Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is upregulated in effector-T-cells after activation that may alter signal transduction and subsequently cytokine production. The present study was designed to investigate the impact of CTLA-4+49 A>G (rs231775), −318 C>T (rs5742909), −658 C>T (rs11571317), −1147 C>T (rs16840252), −1661 A>G (rs4553808), +6230 A>G (rs3087243) SNPs, and microsatellite (AT)n repeat polymorphism among end-stage renal disease (ESRD), acute allograft rejection (AR), and delayed graft function (DGF) cases. In this regard, 350 ESRD patients and 350 controls were included. Polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis method was used for genotyping of CTLA-4 SNPs, while PCR-polyacrylamide gel electrophoresis method was adopted for studying CTLA4 (AT)n polymorphism. The mutant genotype GG of CTLA-4+49A>G,+6230 A>G, and longer alleles of (AT)n repeats polymorphisms were risk associated with ESRD, AR, and DGF cases. The distribution of haplotype+49G:+6230G and GCTTGG (constructed by using 6 studied SNPs) showed risk association for ESRD, DGF, and AR cases. Further, linkage analysis demonstrated strong to moderate linkage disequilibrium in our study populations. The meta-analysis also revealed risk associations for AR cases against GG genotype of CTLA-4+49A>G SNP, while CTLA-4 −318C>T polymorphism showed no correlation against TT genotype among AR cases. Subsequently, no correlation was established against the CTLA-4 −318C>T, −658 C>T, −1147 C>T, and −1661 A>G SNPs in the promoter region. Survival analysis revealed risk associations against GG genotype of CTLA-4+49A>G, +6230 A>G SNP's with overall survival (OS), and higher hazard for the OS. These results suggested that CTLA-4 variants might be involved in susceptibility to ESRD, AR, and DGF.
BarrettJC, FryB, MallerJ, DalyMJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21:263–265.
6.
BenmansourJ, StayoussefM, Al-JenaidiFA, RajabMH, RayanaCB, SaidHB, MahjoubT, AlmawiWY. 2010. Association of single nucleotide polymorphisms in cytotoxic T-lymphocyte antigen 4 and susceptibility to autoimmune type 1 diabetes in Tunisians. Clin Vaccine Immunol, 17(9):1473–1477.
7.
Brunner-WeinzierlMC, HoffH, BurmesterGR. 2004. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases. Arthritis Res Ther, 6:45–54.
8.
CarrenoBM, CollinsM. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol, 20:29–53.
9.
ChenL. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 4:336–347.
10.
ChistiakovDA, SavostanovKV, TurakulovRI, EfremovIA, DemurovLM. 2006. Genetic analysis and functional evaluation of the C/T(−318) and A/G(−1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease. Clin Immunol, 118(2–3):233–242.
DomanskiL, Bobrek-LesiakowskaK, KlodaK, PawlikA, SafranowK, WisniewskaM, RomanowskiM, CiechanowskiK. 2012. The impact of rs231775 (+49AG) CTLA4 gene polymorphism on transplanted kidney function. Ann Transplant, 17(3):29–35.
13.
GaoJW, GuoYF, FanY, QiuJX, BaoED, LiuY, QinY, ZhangF. 2012. Polymorphisms in cytotoxic T lymphocyte associated antigen-4 influence the rate of acute rejection after renal transplantation in 167 Chinese recipients. Transpl Immunol, 26:207–211.
14.
GendzekhadzeK, Rivas-VetencourtP, MontanoRF. 2006. Risk of adverse post-transplant events after kidney allograft transplantation as predicted by CTLA-4+49 and TNF-alpha−308 single nucleotide polymorphisms: a preliminary study. Transpl Immunol, 16:194–199.
GrinyoJ, AlberuJ, ContieriFL, ManfroRC, MondragonG, NainanG, Rial MdelC, SteinbergS, VincentiF, DongY, ThomasD, KamarN. 2012. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int, 25(10):1059–1064.
18.
GuptaR, PrakashS, ParveenF, AgrawalS. 2012. Association of CTLA-4 and TNF-α polymorphism with recurrent miscarriage among North Indian women. Cytokine, 60(2):456–462.
19.
HuangD, GiscombeR, ZhouY, PirskanenR, LefvertAK. 2000. Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis. J Neuroimmunol, 105:69–77.
20.
KameshL, HewardJM, WilliamsJM, GoughSC, ChaveleKM, SalamaA, PuseyC, SavageCO, HarperL. 2009. CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Rheumatology, 48(12):1502–1505.
21.
KimHJ, JeongKH, LeeSH, MoonJY, LeeTW, KangSW, ParkSJ, KimYH, ChungJH. 2010. Polymorphisms of the CTLA4 gene and kidney transplant rejection in Korean patients. Transpl Immunol, 24(1):40–44.
22.
KrichenH, SfarI, Hadj KacemH, BardiR, Jendoubi-AyedS, MakhloufM, Ben RomdhaneT, BesseghairF, AouadiH, Ben AbdallahT, AyadiH, AyedK, GorgiY. 2010. (AT) repeat in the 3′ untranslated region of the CTLA-4 gene and susceptibility to acute allograft rejection in Tunisian renal transplantation. Transplant Proc, 42(10):4314–4317.
23.
KusztalM, Koscielska-KasprzakK, Drulis-FajdaszD, Magott-ProcelewskaM, PatrzałekD, JanczakD, ChudobaP, KlingerM. 2010. The influence of CTLA-4 gene polymorphism on long-term kidney allograft function in Caucasian recipients. Transpl Immunol, 23(3):121–124.
24.
LeiC, DongqingZ, YeqingS, OaksMK, LishanC, JianzhongJ, JieQ, FangD, NingliL, XinghaiH, DamingR. 2005. Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. Eur J Hum Genet, 13(7):823–828.
25.
LigersA, TeleshovaN, MastermanT, HuangWX, HillertJ. 2001. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun, 2:145–152.
26.
MachidaH, TsukamotoK, WenCY, NarumiY, ShikuwaS, IsomotoH, TakeshimaF, MizutaY, NiikawaN, MurataI, KohnoS. 2005. Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol, 11(27):4188–4193.
27.
MaurerM, LoserthS, Kolb-MaurerA, PonathA, WieseS, KruseN, RieckmannP. 2002. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics, 54(1):1–8.
28.
NisticoL, BuzzettiR, PritchardLE, Van der AuweraB, GiovanniniC, BosiE, LarradMT, RiosMS, ChowCC, CockramCS, JacobsK, MijovicC, BainSC, BarnettAH, VandewalleCL, SchuitF, GorusFK, TosiR, PozzilliP, ToddJA. 1996. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet, 5(7):1075–1080.
29.
PalaciosR, ComasD, ElorzaJ, VillosladaP. 2008. Genomic regulation of CTLA4 and multiple sclerosis. J Neuroimmunol, 203(1):108–115.
30.
PandiyanP, GartnerD, SoezeriO, RadbruchA, Schulze-OsthoffK, Brunner-WeinzierlMC. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med, 199(6):831–842.
31.
SaverinoD, BrizzolaraR, SimoneR, ChiapporiA, Milintenda-FlorianiF, PesceG, BagnascoM. 2007. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol, 123(2):190–198.
32.
SesterU, SesterM, HaukM, KaulH, KohlerH, GirndtM. 2000. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant, 15:1217–1223.
StenvinkelP, KettelerM, JohnsonRJ, LindholmB, Pecoits-FilhoR, RiellaM, HeimburgerO, CederholmT, GirndtM. 2005. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int, 67(4):1216–1233.
35.
SunT, ZhouY, YangM, HuZ, TanW, HanX, ShiY, YaoJ, GuoY, YuD, TianT, ZhouX, ShenH, LinD. 2008. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res, 68(17):7025–7034.
36.
TeftWA, KirchhofMG, MadrenasJ. 2006. A molecular perspective of CTLA-4 function. Annu Rev Immunol, 24:65–97.
WallaceBC, SchmidCH, LauJ, TrikalinosTA. 2009. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol, 4(9):80
39.
WangL, LiD, FuZ, LiH, JiangW, LiD. 2007. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer, 7:173
40.
WangXB, KakoulidouM, GiscombeR, QiuQ, HuangD, PirskanenR, LefvertAK. 2002. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol, 130(1–2):224–232.
41.
WangXB, PirskanenR, GiscombeR, LefvertAK. 2008. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med, 263(1):61–69.
42.
WilliamsJD, TopleyN, CraigKJ, MackenzieRK, PischetsriederM, LageC, Passlick-DeetjenJ; Euro Balance Trial Group. 2004. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int, 66(1):408–418.
43.
WisniewskiA, KusztalM, Magott-ProcelewskaM, KlingerM, JasekM, LuszczekW, NowakI, KosmaczewskaA, CiszakL, FrydeckaI, GórskiA, KusnierczykP. 2006. Possible association of cytotoxic T-lymphocyte antigen 4 gene promoter single nucleotide polymorphism with acute rejection of allogeneic kidney transplant. Transplant Proc, 38(1):56–58.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
